AFM24 (EGFR) + atezolizumab in NSCLC - In EGFRwt NSCLC, the Disease Control Rate (DCR) was 76% (25/33 patients), with 48% (16/33) showing tumor shrinkage and an Objective Response Rate (ORR) of 21% (1 CR, 6 PRs)[16] - In EGFRmut NSCLC, the DCR was 71%, with 41% (7/17) showing tumor shrinkage and an ORR of 24% (1 CR, 3 PRs)[16] - Preliminary median Progression-Free Survival (PFS) in EGFRwt NSCLC was 5.6 months, with 36% of patients ongoing[33, 49] - Patients without prior taxane exposure in EGFRwt NSCLC showed a 25% ORR and a preliminary median PFS of 74 months[47, 53] - Post-hoc analysis showed increasing AFM24 exposure resulted in higher ORR, with the highest exposure group (Q4) achieving a 5455% ORR and a 9091% DCR[68] Acimtamig (AFM13) + AlloNK® in r/r HL - In relapsed/refractory Hodgkin Lymphoma (r/r HL), the ORR was 864% (19/22 patients), including a 545% Complete Response (CR) rate[16, 91] - All patients in the LuminICE-203 study were refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPIs)[80] AFM28 in r/r AML - In the highest dose level (300 mg), a composite complete remission rate (CRcR) of 40% (4/10 patients) was achieved in relapsed/refractory Acute Myeloid Leukemia (r/r AML)[16, 107]

Greatness Starts Here We transform organizations by building exceptional leaders, teams, and cultures that get results. © FranklinCovey Co. All rights reserved. PROPRIETARY AND CONFIDENTIAL INVESTOR UPDATE Third Quarter Fiscal 2025 Forward-Looking Statements/Non-GAAP This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon management's current expectations and are subject to various risks and u ...

Gedatolisib: A Novel PAM Inhibitor - Gedatolisib, a pan-PI3K/mTOR inhibitor, shows potential as a highly potent and cytotoxic agent with a differentiated mechanism of action and pharmacokinetic profile[7, 23] - Gedatolisib has demonstrated compelling preliminary results in HR+/HER2- advanced breast cancer (ABC) patients, with a median progression-free survival (mPFS) of 48 months in 1st line and 12.9 months in 2nd line settings[7, 23] - Gedatolisib is more potent against each node than other PAM inhibitors, with >300X higher potency and 1.5x – 2.8x higher cytotoxicity than other PAM inhibitors in vitro[30] - Gedatolisib has a lower rate of Grade 3/4 hyperglycemia (>95% lower) and treatment-related discontinuations (>80% lower) compared to approved PI3K inhibitors[31] Clinical Development and Market Opportunity - Celcuity is conducting a Phase 3 study in 2nd line HR+/HER2- ABC patients and expects to begin enrolling a Phase 3 study in 1st line patients in Q2 2025[7, 158] - The PAM pathway is the most frequently altered pathway in solid tumors (38%), yet drug revenues from PAM inhibitors are a small fraction of other targeted therapy classes[10, 18] - The potential patient population for PAM inhibitors in breast and prostate cancers is estimated to be >500,000 in the US, EU5, and Japan[10] - US market opportunity for Gedatolisib in HR+/HER2- Breast Cancer and Advanced Prostate Cancer is estimated at ~$5-$6 Billion for 2L ABC Post-CDKi + AI, ~$10B+ for 1L ABC ET Sensitive, ~$3B for 1L ABC ET Resistant, $6-$8B for High Risk EBC Adjuvant, $8B+ for 1L/2L mCRPC Post-ARi, $10B+ for 1L mCRPC, $6-$8B for nmCRPC, $10B+ for mHSPC[52] Financial Position - Celcuity has cash, cash equivalents, and short-term investments of $205 million as of Q1 2025, expected to fund operations through 2026[8, 159]

数据显示，汇添富基金旗下1只基金位居数据港十大流通股东。中证上海国企ETF（510810）一季度增 持54.57万股，持有股数185.99万股，占流通股的比例为0.31%。根据测算，今日浮亏损失约91.14万元。 连续3天下跌期间浮亏损失277.13万元。 7月3日，数据港跌2%，截至发稿，报24.06元/股，成交5.57亿元，换手率3.23%，总市值172.84亿元。数 据港股价已经连续3天下跌，区间累计跌幅5.83%。 资料显示，上海数据港股份有限公司位于上海市静安区江场路1401弄14号1601室，成立日期2009年11月 18日，上市日期2017年2月8日，公司主营业务涉及数据中心服务器托管服务及网络带宽服务。主营业务 收入构成为：IDC服务业99.39%，IDC解决方案0.47%，云销售0.14%。 从数据港十大流通股东角度 截至发稿，吴振翔累计任职时间15年152天，现任基金资产总规模189.45亿元，任职期间最佳基金回报 177.69%， 任职期间最差基金回报-31.53%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、 ...

| 索 引 号： | 014495921/2025-01115 | 分 新 | 公示公告；市场监管、应急管理；公告 | | --- | --- | --- | --- | | 发布机构： | 扬中市市场监督管理局 | 发文日期： | 2025-07-02 | | 标 Status and States of Children and | 2025年扬中市市场监督管理局你点我检第二期专项抽检结果汇总表（公示） | | | | 文 号 : | | 公开方式： | 主动公开 | | 内容概述： | 2025年扬中市市场监督管理局你点我检第二期专项抽检结果汇总表（公示） | | | | 时 效 : | | | | | | | | | 2025年扬中市市场监督管理局你点我检专项抽检结果汇总表 | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

Jaguar Health, Inc. (NASDAQ: JAGX) What's Different????? 3 NASDAQ:JAGX • The classic definition of insanity: Doing the same thing over and over again and expecting a different result • Equally crazy — changing the approach and expecting to get the same results Overview – May 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts conta ...

Core Insights - The article discusses the investment positions held by analysts in BTI and MO, indicating a positive outlook on these stocks [1] Group 1 - Analysts have a beneficial long position in the shares of BTI and MO, suggesting confidence in their future performance [1] - The article expresses personal opinions of the author, emphasizing that it is not influenced by external compensation [1]

| 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.07.02 | 3.65 | 32.54 | 4657.40 | | 2025.07.01 | -9.70 | 39.03 | -29785.47 | | 2025.06.30 | 10.02 | 39.11 | -4818.75 | | 2025.06.27 | 9.98 | 47.36 | 19031.46 | | 2025.06.26 | 5.03 | 46.84 | 42389.42 | | 2025.06.25 | -5.77 | 40.16 | -42777.61 | | 2025.06.24 | 10.00 | 41.52 | 44369.03 | | 2025.06.23 | 5.50 | 41.28 | -30349.20 | | 2025.06.20 | 9.99 | 25.88 | -11590.87 | | 2025.06.19 | 9.99 | 2.63 | 11376.51 | | 2025.06.18 | 10.01 | 11.18 ...

This document contains forward-looking statements concerning Eton Pharmaceuticals, Inc. ("Eton", the "Company," "we," "us," and "our"). The words "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following ...

正在吉林 市展出的夫余时期文物。 石洪宇 摄 中新网吉林7月3日电 (记者 石洪宇)记者3日从位于吉林省吉林市的北华大学夫余国历史文化研究中心获 悉，多所高校的专家学者正联手加强夫余国历史文化研究。 公元前2世纪，在中国东北地区诞生了首个夫余政权国家。公元494年，夫余灭国，存国700余年。 北华大学夫余国历史文化研究中心主任宫健泽介绍，学界主流观点认为夫余国的前期王城位于吉林市， 在东团山出土了大量文物，在帽儿山发现了大规模墓葬。这为专家们的研究提供了重要实证依据。 观看夫余时期文物。 石洪宇 摄 近些年，吉林省官方也在多方推动边疆文化研究。在吉林市的东团山遗址展陈馆里，大量文物"诉说"着 夫余文明与中原文明的交流。陶器和瓦片的外形、工艺、花纹，可以证明其生产技术来自中原王朝。 据了解，吉林省计划推动建设夫余研究数字平台，构建"夫余文献数据库"，整合中、日、韩古籍文献。 同时，加强对珍稀文物的保护与修复，推进多个遗址的考古发掘与保护工作。(完) 游客正在 学界认为，夫余族是中国东北地区最早自主跨入文明时代的古民族之一，在中华民族的文明史上占据较 重要地位。 近日在北华大学成立的夫余国历史文化研究中心，旨在厘 ...